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Summary
This report provides a summary of the third meeting of the Harmonising Out-
come Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6–7
April 2013 (HOME III). The meeting addressed the four domains that had previ-
ously been agreed should be measured in every eczema clinical trial: clinical
signs, patient-reported symptoms, long-term control and quality of life. Formal
presentations and nominal group techniques were used at this working meeting,
attended by 56 voting participants (31 of whom were dermatologists). Signifi-
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cant progress was made on the domain of clinical signs. Without reference to
any named scales, it was agreed that the intensity and extent of erythema, excori-
ation, oedema/papulation and lichenification should be included in the core out-
come measure for the scale to have content validity. The group then discussed a
systematic review of all scales measuring the clinical signs of eczema and their
measurement properties, followed by a consensus vote on which scale to recom-
mend for inclusion in the core outcome set. Research into the remaining three
domains was presented, followed by discussions. The symptoms group and qual-
ity of life groups need to systematically identify all available tools and rate the
quality of the tools. A definition of long-term control is needed before progress
can be made towards recommending a core outcome measure.
What’s already known about this topic?
• Many different scales have been used to measure eczema, making it difficult to
compare trials in meta-analyses and hampering improvements in clinical practice.
• HOME core outcome measures must pass the OMERACT (Outcome Measures in
Rheumatology) filter of truth (validity), discrimination (sensitivity to change and
responsiveness) and feasibility (ease of use, costs, time to perform and interpret).
• It has been previously agreed as part of the consensus process that four domains
should be measured by the core outcomes: clinical signs, patient-reported symp-
toms, long-term control and health-related quality of life.
What does this study add?
• Progress was made towards developing a core outcome set for measuring eczema
in clinical trials.
• The group established the essential items to be included in the outcome measure
for the clinical signs of eczema and was able to recommend a scale for the core set.
• The remaining three domains of patient-reported symptoms, long-term control and
health-related quality of life require further work and meetings to determine the
core outcome measures.
This report provides a summary of the third meeting of the Har-
monising Outcome Measures for Eczema (HOME) initiative held
in San Diego, CA, U.S.A. 6–7 April 2013 (HOME III). The HOME
initiative is an international, multidisciplinary group open to any-
one interested in atopic eczema (AE) outcomes research. The aim
of HOME is to develop a consensus-based set of core outcome
measures to be included in all clinical trials of eczema.
This meeting was preceded by two previous meetings:
HOME I (Munich, July 2010)1 where the need for international
consensus was agreed upon, and HOME II (Amsterdam, June
2011)2 where it was agreed by consensus that there would be
a core outcome measure for each of the four domains of clini-
cal signs, patient-reported symptoms, long-term control and
quality of life that should be recorded and reported in every
clinical trial investigating interventions for eczema.
The aims of the HOME III meeting in San Diego were specifi-
cally to:
1 Discuss and interpret new research since the previous
HOME meeting (HOME II) on the four core outcome
domains.
2 Decide which instrument(s) should be used to measure
clinical signs of eczema.
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3 Prioritize areas for further research in the four core
domains.
A separate consensus statement detailing the outcome of the
clinical signs domain has been published elsewhere. The full
minutes of this meeting can be found at www.homeforecze-
ma.org.
Methods
All members of HOME were invited to participate. There were
a total of 56 attendees from around the world: North America
(32), Europe (18), Japan (4) and South America (2). These
included a mixture of prior HOME meeting attendees and
new members. Details by stakeholder group can be found in
Figure 1. Most attendees had been involved with designing or
recruiting into clinical trials (86%) and approximately half
had previously used EASI (Eczema Area and Severity Index)
and/or SCORAD (SCORing Atopic Dermatitis).
A combination of formal presentations and nominal group
techniques were used at the meeting. Consensus was achieved
through an iterative and cumulative process over the 2 days.
The decision was taken prior to the meeting that members
would need to be present in order to vote to ensure that deci-
sions were based on the data presented and the subsequent
discussions.
Each session began with presentations of relevant research,
followed by whole group and breakout group discussions.
Voting was anonymized by using electronic handsets and
TurningPoint© software to analyse the results in real time.
Voting took place as one panel; all stakeholders were included
in every vote. The previously agreed consensus rule2 was
applied here; that is, consensus is reached where fewer than
30% of the voters disagree.
There was no registration fee for the meeting, and no spon-
sorship from any commercial organization was received. With
the exception of patient representatives whose costs were cov-
ered by HOME members, attendees covered their own travel
and accommodation costs.
Patient representatives from France, the U.K. and the U.S.A.
attended the meeting. A lay summary was produced and
circulated prior to the meeting and patient representatives had
time before the meeting to ask any questions about the pro-
cess and content. The patient representatives were then present
at all sessions and participated in the discussion and voting.
Day 1
Session 1: Introduction
Presentation 11. Introduction and background
Professor Hywel Williams (U.K.) opened the meeting by pre-
senting the background to HOME and highlighted that core
outcomes are an essential part of good clinical research to com-
pare outcomes of studies. He then summarized the work
undertaken by HOME members (https://www.ncbi.nlm.nih.
gov/pubmed/25186228) to date and the HOME roadmap,
which describes the steps needed to progress each HOME
workstream. The group was reminded of the need to put aside
preferences and allegiances and to work together as a global
community for the benefit of patients.
Professor Williams also stressed that core outcomes do not
exclude other outcomes being measured in a trial, nor does it
imply that the core outcome has to be a primary outcome;
they are simply the minimum set that should be measured
and reported in all future eczema trials.
Presentation 12. The gift of the OMERACT filter
Dr Jasvinder Singh (U.S.A.) from the OMERACT (Outcome
Measures in Rheumatology) Group acted as an external advi-
sor to keep the meeting focused and fair. Dr Singh explained
the similarities between rheumatoid arthritis research 20 years
ago and eczema research now. He stressed that in the inter-
ests of achieving consensus the group should accept that the
outcome of the consensus may not be perfect but should ask
themselves the question ‘is it preferable to the status quo?’
Fig 1. Breakdown of meeting participants by stakeholder group.
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The core set can be updated over time to reflect new findings
and the measures may be different for children and adults.
Presentation 13. Feasibility in all settings
Professor Kim Thomas (U.K.) highlighted that core outcomes
need to be feasible in all settings and trial designs. The core out-
come set should (i) include at least one objective measure
because not all interventions/trial settings can be blinded; (ii)
be relatively quick and easy to perform with minimal training
required; (iii) perform well; and (iv) measure things of impor-
tance to patients and clinicians. Discussions highlighted that
there was variation in how a representative site was determined.
Presentation 14. The use of global assessments in
eczema research: a systematic review of randomized
controlled trials
Dr Eric Simpson (U.S.A.) explained that the Investigator Global
Assessment (IGA) is required by regulatory agencies to be per-
formed in clinical trials; he presented data from a systematic
review showing that there is huge variation on how IGA is
conducted, and called for standardization. In the discussion
that followed, the group felt that although not a core domain,
the HOME initiative should be involved with helping to stan-
dardize and better validate the IGA.
Session 2: Clinical signs domain
Professor Jochen Schmitt (Germany) stated the objectives of
this session were to (i) achieve consensus on content validity
and (ii) determine which instrument should be included in
the core outcome set to assess clinical signs of eczema in
trials.
Presentation 21. Measuring responsiveness (sensitivity to
change) and minimal clinically important difference of the
Three-Item Severity scale
Dr Mandy Schram (the Netherlands) explained that the Three-
Item Severity (TIS) score3 is quick and easy to administer
because it includes only erythema, oedema and excoriation,
each measured at one representative site. Therefore, because
of the simplicity of the scale, work had been done to look at
the responsiveness of TIS based on previously published trials
and was presented here.
Presentation 22. Measurement properties of outcome
measurements for eczema
Professor Jochen Schmitt (Germany) and Stephanie Deckert
(Germany) presented the results of a systematic review assess-
ing the measurement properties of 16 eczema sign scales. Each
included scale was evaluated using pre-defined criteria includ-
ing the OMERACT filter of truth, discrimination and feasibil-
ity.5 The quality of the methodological studies was assessed
using the COSMIN checklist.6 The two scales that had been
the most extensively validated, and shown to be the most
valid and reliable instruments to assess clinical signs of eczema
were SCORAD7 and EASI.8
The main differences between these two scales were then
discussed: (i) SCORAD uses a representative site whereas EASI
measures the intensity of lesions at four body areas and (ii)
SCORAD relies on the assumption that the extent of eczema
has a linear relationship with severity, which has been shown
not to be the case in all patients.9
Professor Schmitt also described a previous study10 that
showed both intensity and extent of disease should be mea-
sured. There followed an in-depth discussion on the signs
domain that continued into day 2.
Day 2
Session 2: Clinical signs domain (continued)
Day 2 began with putting aside named scales, and a significant
amount of time was dedicated to discussing which signs are
essential to reflect the construct of the disease and should
therefore be included in the core outcome. With reference to
the book Measurement in Medicine,11 Professor Schmitt explained
that when the conceptual framework was considered, signs
were a formative model, because the items of the instrument
form the construct (domain) to be measured. Therefore, con-
tent validity, defined as the degree to which the domain ‘signs’
is comprehensively represented by the items in the instrument,
is crucial. In other words, the items in the instrument all need
to be relevant and all relevant items need to be included.
The main points arising from the discussion are summa-
rized in Table 1.
In the subsequent voting session, consensus was achieved
on the following points (Table S1 for detailed voting results):
1 The core outcome measure for the clinical signs domain
should include erythema, excoriation, oedema/papulation
and lichenification as a minimum to achieve content valid-
ity.
2 Both the intensity and extent of each clinical sign in the
core set should be measured.
3 No other signs are essential to be included, so further
individual signs were not voted on.
Only once there was consensus on the important criterion
of content validity did the discussion move on to which of
the named scales identified in the systematic review met the
criteria for content validity AND standards for validity in other
areas. Professor Schmitt referred back to the systematic review
results to confirm that objective SCORAD and EASI both
include the four essential clinical signs (erythema, excoriation,
oedema/papulation and lichenification) so these two scales
would be shortlisted for consideration. Objective SCORAD was
considered from this point onwards rather than SCORAD
because the purpose here was to identify a scale to measure
only the domain of clinical signs. He also noted that the
© 2014 The Authors. British Journal of Dermatology
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eczema community is very fortunate to have two good and
freely available scales to choose from to measure clinical signs.
An explanation of how to use each of these two scales was
then given to the group (summarized in Table 2).
Nominal group techniques were then used to achieve con-
sensus on which scale to recommend for inclusion in the core
outcome set. The group split into five smaller groups of mixed
nationalities to discuss the two scales. Each small group
reached independent conclusions and voted on their preferred
scale; all five groups voted in favour of EASI.
The small group discussions were then shared with the
group as a whole. EASI was favoured over objective SCORAD
by each group because (i) there is no requirement to identify
a representative site; (ii) it measures only the four essential
signs; (iii) more importance is given to extent; and (iv) dis-
tinguishing between body areas may be important in future
research.
The aim of HOME is to recommend one scale per domain so
the whole group proceeded to vote on whether objective
SCORAD or EASI should be recommended (Table S1 for
detailed voting results).
The result of the vote was 90% in favour of EASI to be rec-
ommended as the core outcome measure for the clinical signs
of eczema (7% in favour of objective SCORAD and 2%
unsure).
The proposal to include both objective SCORAD and EASI in
the core set for a period of time to collect comparative data
on the two scales was not supported (36% voted against)
(Table S1 for detailed voting results).
Session 3: Quality of Life domain
Presentation 31. Quality of Life measures in eczema
clinical care and research
Dr Shehla Admani (U.S.A.) presented a focused review of the
nine most commonly used Quality of Life (QoL) measurement
tools in eczema trials and the properties of each instrument.
Presentation 32. Measurement properties of eczema-
specific measures of health-related quality of life:
systematic review
Dr Christian Apfelbacher (Germany) proposed a protocol to sys-
tematically assess measurement properties of eczema-specific
measures of health-related QoL and identify outcome measures
for eczema-specific QoL. This will follow similar methods to the
signs systematic review4 and will be completed for the HOME
IV meeting.
Discussion
There followed a discussion on the QoL domain. It is clear
that HOME should liaise with the American Association of
Dermatology (AAD) regarding systematic reviews of health-
related QoL being conducted. The use of PROMIS (Patient
Reported Outcomes Measurement Information System) should
be considered (www.nihpromis.org) but internationalization
of the terminology used would be required. It was discussed
that generic scales can perform as well as disease-specific
scales with regard to sensitivity to change but are often not
popular with patients as they can be lengthy to complete. The
fact that different scales may perform better for specific age
groups was highlighted and that work on the QoL domain
should include significant patient input.
Table 1 Summary of main discussion points regarding the signs domain core outcome
The three signs that have previously been shown to be independent predictors of patient-rated disease severity (excoriations, erythema and
oedema/papulation) were all considered to be important signs
In addition, lichenification should also be considered for inclusion because it is often more prominent in darker skin types and reflects the
chronic relapsing nature of the disease
Other signs were discussed, including crusting/oozing, xerosis/dryness, blanching and flaking, and were considered to be less important
It was generally felt that there should be some measure of area involvement in the scale
Discussions suggested that it would be appropriate for the core outcome ‘clinical signs’ to be an investigator-assessed objective measure to
reduce information bias and because the other three domains (symptoms, quality of life and long-term control) are primarily patient-reported
Discussions highlighted that it is important to remember that patient versions of scales are not necessarily the same as investigator versions (e.g.
EASI and self-administered SA-EASI15) and should not be used interchangeably. However, only core outcome measures were under discussion at
this meeting and investigators are free to also include any other scales in addition to the core outcome measures
Table 2 Properties of objective SCORAD and EASI
Objective SCORAD, presented
by Professor Jochen Schmitt
EASI, presented by
Dr Eric Simpson
A representative site is
selected
A score for different
areas of the body for each of
the essential signs is used
(four signs and four body
sites)
Measures six signs: the four
agreed essential signs
plus oozing/crusting and dryness
Measures only the four agreed
essential signs
Gives more weight to intensity
than extent
Signs and extent are
equally weighted
© 2014 The Authors. British Journal of Dermatology
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Session 4: Patient-reported symptoms domain
Dr Phyllis Spuls (the Netherlands) opened the symptoms session
with a definition: a symptom is any feature that is observed by
the patient whereas a sign is observed by other people.
Presentation 41. The use of symptom outcome measures
in eczema research: a systematic review of randomized
controlled trials
Dr Spuls showed that symptoms were reported in three-quarters
of trials published between January 2000 and May 2012, with
itch and sleep loss being the most commonly reported. SCORAD
was the most commonly used named scale to measure symp-
toms but most trials that used SCORAD (92%) did not report
the symptoms separately to the overall composite score.
Presentation 42. Eczema signs and symptoms: what is
important to patients?
Dr Laura von Kobyletzki (Sweden) presented the results of a
web-based survey asking patients and parents/carers in 31
countries to rate the importance of different signs and symp-
toms. Itch and pain were rated the most important, with hot/
inflamed skin, area affected, visible sites, sensitive sites, bleed-
ing, weeping, cracks and sleep difficulties also considered
important.
Presentation 43. Comparison of the visual analogue scale
(VAS) and verbal rating scale in Japanese patients using
VAS with 10-point end of ‘worst imaginable itch’
Dr Norito Katoh (Japan) presented a study showing that there
was significant correlation between the visual analogue scale
(VAS) and the verbal rating scale (VRS) in 949 Japanese patients
with itchy skin diseases. Each category of VRS differed signifi-
cantly from the other categories based on the VAS scoring. While
not directly relating to HOME objectives, this is an example of
where useful work on eczema outcomes is related to HOME.
Discussion
In the subsequent discussion, the next steps towards a consensus
on patient-reported symptoms outcome measure were agreed.
As per the HOME roadmap, this will be to finalize the important
constructs in the symptoms domain, and then a systematic
review of the validation studies on currently available instru-
ments and assessment of the quality of the scales. The overlap
with quality of life should be considered carefully throughout.
Patients highlighted that fatigue is different to sleep loss and that
different symptoms are important to individuals of different
ages.
It was then agreed by voting that itch and sleep loss were
NOT sufficient on their own to reflect the construct of the dis-
ease; other symptoms should also be considered for inclusion.
Table S1 for detailed voting results.
Session 5: Long-term control domain
Professor Kim Thomas began by emphasizing the need to
agree on the definition of ‘long-term control’ and determine
whether it is truly a separate domain or simply a repeated
measurement of other core outcomes. Options for measuring
long-term control include flares, escalation of treatment, well-
controlled weeks and accessing health resources, but the out-
come measure needs to suit trials of all durations and reflect
that eczema is a chronic disease. There are parallels with
asthma where researchers have recently published a consensus
on using ‘escalation of therapy’ as an indicator of control.12
Presentation 51. Systematic review of flare definitions
used in prospective studies. ‘How should eczema “flares”
be defined?’ Implications for the design and conduct of
trials
Professor Thomas presented data from a systematic review
showing that of the 26 included studies, 21 different flare def-
initions were used. Flares, as currently defined, may not be a
good contender for the long-term control domain, particularly
for trials with long follow-up or minimal patient contact, as
there are difficulties in collecting the data required.
Presentation 52. A validation study of a flare definition
based on the need to escalate treatment as a result of
worsening disease control
Professor Thomas presented results of a validation study to test
the previously published definition of flare: ‘escalation of ther-
apy due to worsening of disease’. This intuitively understood
concept correlated moderately well with other eczema severity
scales (Patient Oriented Eczema Measure, POEM),13 Three-
Item Severity (TIS)3 and Six Area, Six Sign Atopic Dermatitis
(SASSAD).14 However, it does require resource-intensive com-
pletion of daily diaries so may not be suitable for all settings.
Presentation 53. Validation study of well-controlled
weeks as a way of measuring long-term control
The final presentation from Professor Thomas focused on
assessment of well-controlled weeks and how well this per-
forms in capturing long-term control. Although the concept
of well-controlled weeks is intuitive and well understood, the
data collection and management is complex and resource-
intensive so may not be suitable in all trial settings.
Nevertheless, similar to flares, well-controlled weeks
correlated moderately well with other eczema severity scales
(POEM, TIS and SASSAD).
Discussion
The relative merits of the two broad approaches to measuring
long-term control of eczema were discussed and are summa-
rized in Table 3.
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There is great variation in how people define long-term
control including stable disease over a period of months, lack
of need for escalation of treatment/rescue therapy, number
and duration of flares, duration of the trial (long-term) and
repeated measurement of the other three core outcome
domains. It was agreed by voting that the next stage is to con-
duct a systematic review to establish how long-term control
has been captured in other trials (and possibly other long-
term prospective studies) followed by a systematic review of
validation studies. Voting suggested that long-term control is a
unique concept that requires its own outcome tool but there
was mixed opinion regarding whether long-term control
should be completed exclusively by patients and how often
long-term control should be measured. It was agreed this
domain should apply to trials of more than 3 months’ dura-
tion. Details of the voting results can be found in Table S1.
Meeting close
Professor Hywel Williams closed the meeting by summing
up the progress of each domain and commented that the
group had worked well together with everyone contributing.
The meeting benefited from input of patients and caregivers,
and indicated that the independent and expert input of Jas
Singh from OMERACT was invaluable. He concluded by
reminding the group that the ultimate aim of the HOME ini-
tiative is to help patients and this should always be remem-
bered.
Limitations and dissenting opinions
Limitations of these findings include the possibility that the
HOME meeting did not fully represent all stakeholders inter-
ested in eczema. The HOME initiative attempts to reduce bias
by holding meetings that include a diverse group of research-
ers, clinicians, regulatory and industry representatives, patients
and patient advocates. Meetings are held in different areas of
the world with no registration fees and are open to anyone
interested in eczema. Researchers who are not able to partici-
pate are encouraged to send a representative for voting pur-
poses. Only those participating in the meeting are able to vote
as HOME meetings involve presentation of new and emerging
evidence, and employ nominal group techniques and elec-
tronic voting to achieve consensus. These meeting procedures
were developed after consultation with key leaders of OME-
RACT – a core outcome group with over 20 years of experi-
ence in core outcome set development.
In achieving global consensus it is important to listen to the
voice of ‘dissenters’ as well as those in agreement with the
consensus view. After HOME III, the HOME group received
feedback from some colleagues with a strong interest in
SCORAD that they did not agree with the recommendation to
use EASI as the preferred outcome scale for assessment of clin-
ical signs.
We would like to stress that both the EASI and objective
SCORAD were evaluated during the HOME III meeting as
being valid and reliable tools for the objective assessment of
eczema clinical signs, and would like to reassure readers that
use of EASI as the recommended core outcome measure does
not preclude the use of other outcome measures in future tri-
als alongside the EASI. It should also be stressed that patient-
reported outcomes (including symptoms and quality of life)
will be discussed at future HOME meetings with a view to
establishing the best instruments for evaluating these domains.
Consensus was reached that clinical signs should be assessed
using an objective outcome measure, in order to protect
against reporting bias in trials where participants are aware of
their treatment allocation.
Table 3 Summary of discussion on different ways of measuring long-term control
Measure of flares/well-controlled weeks
Repeated serial measurements of the other three
domains (signs, symptoms and QoL)
Measurement of flares should be a patient-reported outcome (PRO) because
a flare is a significant event for patients and so they are well placed to
determine when a flare has occurred. Trials often do not have enough
clinic visits to enable flares to be measured by the investigator
This could be an attractive and efficient way of measuring
long-term control if the other domains are already being
captured in the trial
There is variability between patients in how they define a flare so individual
flare definitions may be needed in a trial. It should be remembered that
patients can have poor control without a flare
Scales would need to be completed frequently enough to
capture the fluctuations in the eczema which may impact
on the feasibility of this approach
A definition of a flare (including the end of a flare) needs to be agreed on
if it is to be used
The EASI scale captures only the eczema at that moment, so
to capture signs over the long term, frequent trial visits
with the investigator would be required
Parents can sometimes get confused about whether questions on well-controlled
weeks refer to the eczema or the child’s behaviour
There are many ways these data can be analysed to measure
long-term control (e.g. mixed models, fixed-effect models)
Need to determine whether or not the floor effect is important because trials
are measuring a benefit
Does not reflect any changes in treatment
Existing trial data where a mixture of daily, weekly and monthly data have been
collected should be used to establish the frequency of data collection needed
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Next steps
Although HOME III focused on the clinician-reported signs, the
patient-reported domains of symptoms and quality of life, and
the long-term control domain will be the focus of future HOME
meetings. Prior to the HOME IV meeting, individual working
groups will conduct systematic reviews and further validation
studies to inform discussions over the most appropriate tools
for measuring these remaining core domains. In relation to the
EASI, efforts will now focus on disseminating and sharing the
consensus view with researchers, journal editors and regulatory
authorities. Standardized training resources will be developed
and made available via the HOME website, along with summary
data to inform sample-size calculations in different patient pop-
ulations.
The HOME group will continue to encourage members
from nationalities currently not represented, and other clini-
cians involved in the management of eczema, to join the
group and attend meetings. The HOME project has always
been, and will remain, open to views from all stakeholders
interested in the development of core outcome sets for
eczema.
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